Mediclinic International 2017 interim results

DividendMax Ltd.

Mediclinic International 2017 interim results


27% increase in Group revenue of which 16% was contributed by Al Noor

Strong performance in Switzerland with revenue up 5% and underlying EBITDA up 7%

Good organic growth in Southern Africa supported by infrastructure investment

Middle East business impacted by new insurance co-payment requirement, doctor vacancies and delayed facility openings

Integration of Al Noor on track to deliver AED75m of annualised synergies

Underlying EBITDA up 11% to £220m

Operating profit up 10% to £169m

Underlying earnings per share decreased by 26% to 12.8 pence, largely impacted by the shares issued to acquire and adverse operating performance of Al Noor

Cash flow conversion 95% of underlying EBITDA

Interim dividend per ordinary share up to 3.20 pence

Continued investments to improve patient experience and clinical quality

Companies mentioned